Shares of AC Immune SA (NASDAQ:ACIU) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus target price of $26.00 for the company, according to Zacks. Zacks has also assigned AC Immune an industry rank of 199 out of 265 based on the ratings given to related companies.
A number of brokerages have recently issued reports on ACIU. BidaskClub upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. Zacks Investment Research upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Monday, February 5th.
Institutional investors and hedge funds have recently modified their holdings of the business. Tekla Capital Management LLC raised its stake in AC Immune by 319.9% during the fourth quarter. Tekla Capital Management LLC now owns 171,813 shares of the company’s stock worth $2,199,000 after purchasing an additional 130,894 shares during the period. Renaissance Technologies LLC purchased a new position in AC Immune during the fourth quarter worth approximately $143,000. Belpointe Asset Management LLC purchased a new position in AC Immune during the third quarter worth approximately $571,000. Janney Montgomery Scott LLC purchased a new position in AC Immune during the third quarter worth approximately $134,000. Finally, Wells Fargo & Company MN purchased a new position in AC Immune during the third quarter worth approximately $111,000. Institutional investors own 19.63% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AC Immune SA (ACIU) Receives Average Recommendation of “Strong Buy” from Analysts” was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3260608/ac-immune-sa-aciu-receives-average-recommendation-of-strong-buy-from-analysts.html.
AC Immune Company Profile
AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.